<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>94(8)</volume><submitter>Lai EW</submitter><funding>Intramural NIH HHS</funding><pubmed_abstract>&lt;h4>Context&lt;/h4>Pheochromocytomas and paragangliomas are rare catecholamine-secreting neuroendocrine tumors arising from the adrenal medulla and sympathetic tissues. When complete surgical resection is not an option, the treatment of pheochromocytoma is limited.&lt;h4>Objective&lt;/h4>The objective of the study was to identify and characterize overexpression of IL-13 receptor-alpha2 (IL-13Ralpha2) gene expression in human and murine tumors and verify xenograft mouse pheochromocytoma cell (MPC)-derived tumor's response to a selective cytotoxin.&lt;h4>Design/setting/patients&lt;/h4>Expression of IL-13Ralpha2 was evaluated in a panel of 25 human pheochromocytoma clinical samples by RT-PCR and eight MPC tumors by indirect immunofluorescence assay and RT-PCR.&lt;h4>Intervention&lt;/h4>The function of IL-13Ralpha</pubmed_abstract><journal>The Journal of clinical endocrinology and metabolism</journal><pagination>2952-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2730867</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.</pubmed_title><pmcid>PMC2730867</pmcid><pubmed_authors>Leland P</pubmed_authors><pubmed_authors>Joshi BH</pubmed_authors><pubmed_authors>Fujisawa T</pubmed_authors><pubmed_authors>Lai EW</pubmed_authors><pubmed_authors>Elkahloun AG</pubmed_authors><pubmed_authors>de Krijger RR</pubmed_authors><pubmed_authors>Lubensky IA</pubmed_authors><pubmed_authors>Puri RK</pubmed_authors><pubmed_authors>Martiniova L</pubmed_authors><pubmed_authors>Morris JC</pubmed_authors><pubmed_authors>Pacak K</pubmed_authors><pubmed_authors>Dogra R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.</name><description>&lt;h4>Context&lt;/h4>Pheochromocytomas and paragangliomas are rare catecholamine-secreting neuroendocrine tumors arising from the adrenal medulla and sympathetic tissues. When complete surgical resection is not an option, the treatment of pheochromocytoma is limited.&lt;h4>Objective&lt;/h4>The objective of the study was to identify and characterize overexpression of IL-13 receptor-alpha2 (IL-13Ralpha2) gene expression in human and murine tumors and verify xenograft mouse pheochromocytoma cell (MPC)-derived tumor's response to a selective cytotoxin.&lt;h4>Design/setting/patients&lt;/h4>Expression of IL-13Ralpha2 was evaluated in a panel of 25 human pheochromocytoma clinical samples by RT-PCR and eight MPC tumors by indirect immunofluorescence assay and RT-PCR.&lt;h4>Intervention&lt;/h4>The function of IL-13Ralpha</description><dates><release>2009-01-01T00:00:00Z</release><publication>2009 Aug</publication><modification>2025-04-05T11:53:17.707Z</modification><creation>2019-03-26T23:59:14Z</creation></dates><accession>S-EPMC2730867</accession><cross_references><pubmed>19491224</pubmed><doi>10.1210/jc.2009-0309</doi></cross_references></HashMap>